Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.
Biomarker and diagnostic research for amyloidosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
309 clinical trials registered, 157 recruiting. Interventions under study include other interventions, drug therapy, biologic therapy, and procedural interventions. Pipeline includes 11 PHASE4, 31 PHASE3, 44 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07079423](https://clinicaltrials.gov/study/NCT07079423) |
Data assembled from 4 of 12 sources · Last updated Nov 3, 2026, 6:00 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis |
PHASE2 |
Peking Union Medical College Hospital |
RECRUITING |
[NCT06458374](https://clinicaltrials.gov/study/NCT06458374) | ATTR Cardiac Amyloidosis in a Selected Population | — | Helse Møre og Romsdal HF | RECRUITING |
[NCT07223203](https://clinicaltrials.gov/study/NCT07223203) | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | PHASE3 | Alnylam Pharmaceuticals | RECRUITING |
[NCT07154381](https://clinicaltrials.gov/study/NCT07154381) | Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis | — | University Hospital, Essen | RECRUITING |
[NCT06192979](https://clinicaltrials.gov/study/NCT06192979) | Optimize First-line Treatment for AL Amyloidosis With t (11; 14) | NA | Jin Lu, MD | RECRUITING |
500 publications have been identified in PubMed for amyloidosis. Research spans Review / Meta-Analysis (37%), Basic Science / Preclinical (17%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 186 | 37% |
Laboratory research | 83 | 17% |
Disease patterns and progression | 73 | 15% |
Patient case studies | 51 | 10% |
Clinical study results | 50 | 10% |
Testing and diagnosis research | 48 | 10% |
New treatment approaches | 6 | 1% |
Other research | 3 | 1% |
Sinigiani G (2026). [PMID: 41168058](https://pubmed.ncbi.nlm.nih.gov/41168058/). *Eur J Intern Med*. [Review / Meta-Analysis]
Kafil TS (2026). [PMID: 41236415](https://pubmed.ncbi.nlm.nih.gov/41236415/). *Curr Opin Cardiol*. [Review / Meta-Analysis]
Grabher BJ (2026). [PMID: 41667282](https://pubmed.ncbi.nlm.nih.gov/41667282/). *J Nucl Med Technol*. [Review / Meta-Analysis]
Yamamoto N (2026). [PMID: 41962876](https://pubmed.ncbi.nlm.nih.gov/41962876/). *Biochim Biophys Acta Proteins Proteom*. [Basic Science / Preclinical]
Fontana M (2026). [PMID: 41212997](https://pubmed.ncbi.nlm.nih.gov/41212997/). *Circulation*. [Clinical Trial Publication]
Razvi Y (2026). [PMID: 41528278](https://pubmed.ncbi.nlm.nih.gov/41528278/). *JACC Heart Fail*. [Diagnostic / Biomarker]
Meier C (2026). [PMID: 42041978](https://pubmed.ncbi.nlm.nih.gov/42041978/). *J Cardiovasc Dev Dis*. [Review / Meta-Analysis]
Kind A (2026). [PMID: 42197844](https://pubmed.ncbi.nlm.nih.gov/42197844/). *Sensors (Basel)*. [Review / Meta-Analysis]
Katzianer DS (2026). [PMID: 40945551](https://pubmed.ncbi.nlm.nih.gov/40945551/). *Cardiovasc Pathol*. [Epidemiology / Natural History]
Giamundo DM (2026). [PMID: 40985278](https://pubmed.ncbi.nlm.nih.gov/40985278/). *Eur J Clin Invest*. [Review / Meta-Analysis]
AI-curated news mentioning amyloidosis
Updated Oct 8, 2026
Recent research highlights the clinical manifestations and cardiac abnormalities associated with systemic Amyloid A amyloidosis. This study provides valuable insights into the disease's impact on heart function, which could inform future therapeutic strategies.
A North Texas man with AL Amyloidosis achieved complete remission after participating in a clinical trial for CAR-T cell therapy, NX 201. The trial reported a striking 95% remission rate among participants, highlighting the potential of this innovative treatment for a rare and life-threatening condition.
A clinical trial of CAR-T cell therapy NXC-201 shows promising results for patients with AL Amyloidosis, with approximately 95% achieving complete remission. This innovative treatment targets the accumulation of abnormal proteins that damage vital organs.
A clinical trial of CAR-T cell therapy, NX 201, shows promising results for patients with AL amyloidosis, with about 95% achieving complete remission. This experimental treatment could significantly impact the management of this rare and life-threatening disease.
A recent study highlights systemic light chain amyloidosis as a rare cause of jejunal perforation, emphasizing the need for awareness among clinicians. This discovery may lead to improved diagnosis and management strategies for affected patients.